(VIANEWS) – Shares of ULTIMOVACS (Oslo Børs Benchmark Index_GI: ULTI.OL) slid by a staggering 31.62% to kr80.00 at 11:37 EST on Thursday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI is jumping 0.22% to kr1,230.30, following the last session’s upward trend. This seems, up until now, a somewhat bullish trend exchanging session today.
ULTIMOVACS’s last close was kr117.00, 17.95% below its 52-week high of kr142.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-4.57.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.74%.
Yearly Top and Bottom Value
ULTIMOVACS’s stock is valued at kr80.00 at 11:37 EST, way under its 52-week high of kr142.60 and way above its 52-week low of kr58.50.
Volatility
ULTIMOVACS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.11%, a negative 0.43%, and a positive 1.90%.
ULTIMOVACS’s highest amplitude of average volatility was 1.70% (last week), 1.57% (last month), and 1.90% (last quarter).
Moving Average
ULTIMOVACS’s worth is way under its 50-day moving average of kr121.26 and way below its 200-day moving average of kr101.44.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ULTIMOVACS’s stock is considered to be overbought (>=80).
More news about ULTIMOVACS (ULTI.OL).
